DK1007638T3 - KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf - Google Patents

KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf

Info

Publication number: DK1007638T3
Authority: DK; Denmark
Prior art keywords: kcnq2; proteins; kcnq3; potassium channels; disease
Prior art date: 1997-08-12

Application number

DK98932877T

Other languages

English (en)

Inventor

Steven Dworetzky

Valentin K Gribkoff

Wen-Pin Yang

Michael A Blanar

Paul C Levesque

Michael G Neubauer

Wayne A Little

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-12

Filing date

1998-06-26

Publication date

2007-05-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21998937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1007638(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-26 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-05-21 Application granted granted Critical

2007-05-21 Publication of DK1007638T3 publication Critical patent/DK1007638T3/da

Links

102000012359 KCNQ Potassium Channels Human genes 0.000 title 1
108010022282 KCNQ Potassium Channels Proteins 0.000 title 1
102000005453 KCNQ2 Potassium Channel Human genes 0.000 abstract 3
108010006746 KCNQ2 Potassium Channel Proteins 0.000 abstract 3
102000015686 KCNQ3 Potassium Channel Human genes 0.000 abstract 2
108010038888 KCNQ3 Potassium Channel Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000000044 Amnesia Diseases 0.000 abstract 1
206010003591 Ataxia Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
101000994667 Homo sapiens Potassium voltage-gated channel subfamily KQT member 2 Proteins 0.000 abstract 1
101000994663 Homo sapiens Potassium voltage-gated channel subfamily KQT member 3 Proteins 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
241001529936 Murinae Species 0.000 abstract 1
206010028632 Myokymia Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
102000004257 Potassium Channel Human genes 0.000 abstract 1
101100397814 Rattus norvegicus Kcnq2 gene Proteins 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
208000032257 benign familial neonatal 1 seizures Diseases 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
102000053004 human KCNQ2 Human genes 0.000 abstract 1
102000053006 human KCNQ3 Human genes 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
208000005264 motor neuron disease Diseases 0.000 abstract 1
210000000653 nervous system Anatomy 0.000 abstract 1
230000004112 neuroprotection Effects 0.000 abstract 1
108020001213 potassium channel Proteins 0.000 abstract 1
230000005062 synaptic transmission Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK98932877T 1997-08-12 1998-06-26 KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf DK1007638T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5559997P	1997-08-12	1997-08-12
PCT/US1998/013276 WO1999007832A1 (en)	1997-08-12	1998-06-26	Kcnq potassium channels and methods of modulating same

Publications (1)

Publication Number	Publication Date
DK1007638T3 true DK1007638T3 (da)	2007-05-21

Family

ID=21998937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98932877T DK1007638T3 (da)	1997-08-12	1998-06-26	KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf

Country Status (10)

Country	Link
US (4)	US6403360B1 (da)
EP (1)	EP1007638B1 (da)
JP (1)	JP2001512673A (da)
AT (1)	ATE356200T1 (da)
AU (1)	AU731087B2 (da)
CA (1)	CA2300985A1 (da)
DE (1)	DE69837267T2 (da)
DK (1)	DK1007638T3 (da)
ES (1)	ES2281129T3 (da)
WO (1)	WO1999007832A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1007638T3 (da) *	1997-08-12	2007-05-21	Bristol Myers Squibb Co	KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf
CA2307316C (en) *	1997-10-24	2010-12-21	University Of Utah Research Foundation	Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
WO2000061606A1 (en) *	1999-04-14	2000-10-19	Merck & Co., Inc.	Novel human voltage-gated potassium channel
US6649371B1 (en)	1999-06-11	2003-11-18	Neurosearch A/S	Potassium channel KCNQ5 and sequences encoding the same
ATE374212T1 (de) *	1999-06-11	2007-10-15	Neurosearch As	Neue kalium-kanäle und dafür kodierende gene
US6472165B1 (en)	1999-08-03	2002-10-29	Arzneimittelwerk Dresden Gmbh	Modulatory binding site in potassium channels for screening and finding new active ingredients
NZ527771A (en)	1999-08-04	2005-04-29	Icagen Inc	Methods for treating or preventing anxiety
DE10013732A1 (de) *	2000-03-21	2001-09-27	Aventis Pharma Gmbh	Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems
US7049137B2 (en) *	2000-03-21	2006-05-23	Icagen, Inc.	KCNQ5, a novel potassium channel
US6617131B2 (en)	2000-03-21	2003-09-09	Aventis Pharma Deutschland Gmbh	Nucleic acid molecule encoding the potassium channel protein, KCNQ5
EP1272634A1 (en) *	2000-04-03	2003-01-08	Lexicon Genetics Incorporated	Human ion channel protein and polynucleotides encoding the same
WO2001092526A1 (en) *	2000-05-26	2001-12-06	Bristol-Myers Squibb Company	Human kcnq5 potassium channel, methods and compositions thereof
TWI287984B (en) *	2000-10-17	2007-10-11	Wyeth Corp	Pharmaceutical composition for modulating bladder function
MXPA03007397A (es)	2001-02-20	2003-12-04	Bristol Myers Squibb Co	Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
UA114592C2 (uk) *	2010-09-28	2017-07-10	Ноно Інк.	Пептид nd2 та спосіб лікування неврологічного захворювання
FR3029113A1 (fr) *	2014-12-02	2016-06-03	Univ Paris-Sud	Composes pour le traitement des maladies mitochondriales
WO2021178769A1 (en) *	2020-03-06	2021-09-10	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating kcnq2
WO2025198930A1 (en) *	2024-03-18	2025-09-25	Humanwell Pharmacuetical Us, Inc.	Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09191882A (ja)	1996-01-16	1997-07-29	Japan Tobacco Inc	ヒト新規ｋ＋チャネル蛋白質をコードするｄｎａおよびその断片
DK1007638T3 (da) *	1997-08-12	2007-05-21	Bristol Myers Squibb Co	KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf
CA2307316C (en) *	1997-10-24	2010-12-21	University Of Utah Research Foundation	Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies

1998
- 1998-06-26 DK DK98932877T patent/DK1007638T3/da active
- 1998-06-26 JP JP2000506317A patent/JP2001512673A/ja active Pending
- 1998-06-26 CA CA002300985A patent/CA2300985A1/en not_active Abandoned
- 1998-06-26 AU AU82665/98A patent/AU731087B2/en not_active Ceased
- 1998-06-26 EP EP98932877A patent/EP1007638B1/en not_active Revoked
- 1998-06-26 AT AT98932877T patent/ATE356200T1/de active
- 1998-06-26 DE DE69837267T patent/DE69837267T2/de not_active Revoked
- 1998-06-26 WO PCT/US1998/013276 patent/WO1999007832A1/en not_active Ceased
- 1998-06-26 ES ES98932877T patent/ES2281129T3/es not_active Expired - Lifetime
- 1998-06-26 US US09/105,058 patent/US6403360B1/en not_active Expired - Lifetime
2002
- 2002-04-24 US US10/131,685 patent/US7262289B2/en not_active Expired - Fee Related
- 2002-04-24 US US10/128,870 patent/US7041496B2/en not_active Expired - Lifetime
2007
- 2007-02-16 US US11/707,363 patent/US7482431B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1007638B1 (en)	2007-03-07
US20020168724A1 (en)	2002-11-14
WO1999007832A1 (en)	1999-02-18
ATE356200T1 (de)	2007-03-15
US7041496B2 (en)	2006-05-09
US6403360B1 (en)	2002-06-11
US7262289B2 (en)	2007-08-28
AU8266598A (en)	1999-03-01
CA2300985A1 (en)	1999-02-18
EP1007638A4 (en)	2004-12-29
EP1007638A1 (en)	2000-06-14
AU731087B2 (en)	2001-03-22
DE69837267T2 (de)	2007-10-31
US20070148692A1 (en)	2007-06-28
US7482431B2 (en)	2009-01-27
ES2281129T3 (es)	2007-09-16
US20030044912A1 (en)	2003-03-06
DE69837267D1 (de)	2007-04-19
JP2001512673A (ja)	2001-08-28

Similar Documents

Publication	Publication Date	Title
EP1007638A4 (en)	2004-12-29	KCNQ POTASSIUM CHANNELS AND METHOD FOR CHANGING THEM
MXPA02001911A (es)	2003-07-21	Anticuerpos ctla-4 humanos y sus usos.
DE69637256D1 (de)	2007-10-31	Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
DE69841653D1 (de)	2010-06-17	Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
NO970042D0 (no)	1997-01-06	2-£(Dihydro)pyrazolyl-3'-oksymetylen\|-anilider, fremgangsmåte til fremstilling og anvendelse derav
WO2004058704A8 (en)	2005-10-27	Quinazolinones as potassium channel modulators
IL152663A0 (en)	2003-06-24	Novel multicyclic compounds and the use thereof
DE69626539D1 (de)	2003-04-10	topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
WO2001001970A3 (en)	2002-02-28	New uses potassium channel openers, such as the treatment of epilepsy
BG105012A (en)	2001-08-31	N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
WO2002076494A3 (en)	2002-12-12	USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
ATE299179T1 (de)	2005-07-15	Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung
WO2001031008A3 (en)	2002-03-07	Human and rat fgf-20 genes and gene expression products
EA200001246A1 (ru)	2001-08-27	Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот
TR199802019T2 (xx)	1999-04-21	Terap�tik amidleri stereoselektif olarak haz�rlamak i�in enzimatik y�ntem.
DE69808475D1 (de)	2002-11-07	Aminosäurederivate zur behandlung von schlaganfall
ATE291621T1 (de)	2005-04-15	Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
ATE550345T1 (de)	2012-04-15	Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
BR9704615A (pt)	2006-03-14	formononetina de metal alcalino e processo de estimulação micorrizal
WO2003040320A3 (en)	2004-08-19	Antisense modulation of human collapsin response mediator protein 2 expression
EP1191096A4 (en)	2004-06-02	NEW PROTEIN AND ITS DNA
WO2005002573A3 (en)	2005-06-30	Methods for using modulators of proline-rich tyrosine kinase 2
ATE391915T1 (de)	2008-04-15	Verwendung des proteins grf-1 zur auswahl von molekülen
DE59808160D1 (de)	2003-06-05	Zusammensetzung zur behandlung von gegerbtem leder, sowie ihre herstellung
DZ2783A1 (fr)	2005-10-08	Procédé pour obtenir de l'érythropoïetine humaine recombinante et l'érythropoïetine ainsi obtenue.